FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / Equine interferon gamma synthesis in lymphocytes after in vi...
Vaccine2005; 23(36); 4541-4551; doi: 10.1016/j.vaccine.2005.03.048

Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1.

Abstract: Equine cytotoxic T lymphocyte (CTL) responses to equine herpesvirus-1 (EHV-1) are well characterised but little is known about the cytokine response after infection or vaccination. EHV-1 is common in horses and infects lymphocytes in vivo. This virus was used as a model to measure the synthesis of interferon gamma (IFN-gamma) by equine peripheral blood mononuclear cells (PBMC) after in vivo infection and/or in vitro stimulation with EHV-1. Both flow cytometry and ELISPOT assays were used to quantify equine IFN-gamma using a mouse anti-bovine IFN-gamma monoclonal antibody (clone CC302; shown to cross-react with recombinant equine IFN-gamma) and a rabbit anti-canine IFN-gamma polyclonal antibody. The percentage of PBMC synthesising IFN-gamma after in vitro stimulation with EHV-1 increased with age. In yearlings infected experimentally with EHV-1, PBMC showed two peaks of IFN-gamma synthesis, 11 and 56 days after infection. The IFN-gamma synthesis was principally associated with CD8(+) cells. The patterns of IFN-gamma synthesis detected by intracellular IFN-gamma staining or ELISPOT were compared with CTL data and shown to be similar. These methods were also applied successfully to frozen samples of PBMC. Measurement of equine IFN-gamma using these simple techniques can now be applied to future studies on protective cellular immune responses following virus infection and/or vaccination of horses.
Get Full Text
Publication Date: 2005-05-26 PubMed ID: 15913852DOI: 10.1016/j.vaccine.2005.03.048Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study focuses on the response of the immune system—specifically the production of Interferon gamma (IFN-gamma)—of horses to equine herpesvirus-1 (EHV-1). The response patterns post-infection or post-vaccination were analyzed to gain a deeper understanding of equine immune responses.

Detailed Summary of the Research Article

  • In this study, the researchers presented anothorough analysis of the response of equine immune cells, specifically cytotoxic T cells, to equine herpesvirus-1 (EHV-1).
  • EHV-1 is a common virus in horses and affects lymphocytes, a type of immune cell, in horses. This research provides insights into the production of Interferon gamma (IFN-gamma), a key protein involved in immune responses, by horse immune cells in response to EHV-1.
  • The team used EHV-1 as a model to track the production synthesis of IFN-gamma by equine peripheral blood mononuclear cells (PBMC)—a type of immune cell—after they were infected or stimulated with EHV-1 in lab conditions.

    • Methods and Findings

    • The researchers applied two different procedures—flow cytometry and ELISPOT assays—to quantify equine IFN-gamma. They relied on antibodies that have been demonstrated to react with IFN-gamma from other animals.
    • The research revealed that the percentage of PBMCs producing IFN-gamma after in vitro EHV-1 stimulation increased with the horse’s age. Yearlings (young horses) experimentally infected with EHV-1 showed two peaks of IFN-gamma synthesis—11 and 56 days after the infection. The synthesis was primarily linked to a sub-type of T cells, CD8+ cells.
    • The patterns identified directly corresponded with the cytotoxic T cell response data previously reported. This implies that IFN-gamma plays a critical role in immune system responses to EHV-1 in horses, as it does in other species.

    Implications of the Research

    • The research provides crucial insights into the equine immune response, particularly the role IFN-gamma plays following virus infection or vaccination.
    • Understanding these patterns can help develop new or enhanced strategies for equine disease prevention or treatment, particularly for viral diseases such as EHV-1.
    • Scientists can apply the simple techniques used to measure equine IFN-gamma in this study to future research on protective cellular immune responses. This study lays the groundwork for investigations into how horses and potentially other species respond to virus infection and/or vaccination.

Cite This Article

APA
Paillot R, Daly JM, Juillard V, Minke JM, Hannant D, Kydd JH. (2005). Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine, 23(36), 4541-4551. https://doi.org/10.1016/j.vaccine.2005.03.048

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 23
Issue: 36
Pages: 4541-4551

Researcher Affiliations

Paillot, R
  • Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK. romain.paillot@aht.org.uk
Daly, J M
    Juillard, V
      Minke, J M
        Hannant, D
          Kydd, J H

            MeSH Terms

            • Age Factors
            • Animals
            • Cryopreservation
            • Herpesviridae Infections / immunology
            • Herpesviridae Infections / prevention & control
            • Herpesviridae Infections / veterinary
            • Herpesvirus 1, Equid / immunology
            • Horse Diseases / immunology
            • Horse Diseases / prevention & control
            • Horses
            • Interferon-gamma / biosynthesis
            • Leukocytes, Mononuclear / immunology
            • Lymphocytes / immunology
            • Male
            • T-Lymphocytes, Cytotoxic / immunology

            Citations

            This article has been cited 17 times.
            1. El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines (Basel) 2022 May 26;10(6).
              doi: 10.3390/vaccines10060855pubmed: 35746463google scholar: lookup
            2. Lee DH, Lee EB, Seo JP, Ko EJ. Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines. J Anim Sci Technol 2022 May;64(3):588-598.
              doi: 10.5187/jast.2022.e30pubmed: 35709134google scholar: lookup
            3. Pavulraj S, Kamel M, Stephanowitz H, Liu F, Plendl J, Osterrieder N, Azab W. Equine Herpesvirus Type 1 Modulates Cytokine and Chemokine Profiles of Mononuclear Cells for Efficient Dissemination to Target Organs. Viruses 2020 Sep 8;12(9).
              doi: 10.3390/v12090999pubmed: 32911663google scholar: lookup
            4. Schnabel CL, Babasyan S, Rollins A, Freer H, Wimer CL, Perkins GA, Raza F, Osterrieder N, Wagner B. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease. J Virol 2019 Nov 15;93(22).
              doi: 10.1128/JVI.01011-19pubmed: 31462575google scholar: lookup
            5. Wimer CL, Schnabel CL, Perkins G, Babasyan S, Freer H, Stout AE, Rollins A, Osterrieder N, Goodman LB, Glaser A, Wagner B. The deletion of the ORF1 and ORF71 genes reduces virulence of the neuropathogenic EHV-1 strain Ab4 without compromising host immunity in horses. PLoS One 2018;13(11):e0206679.
              doi: 10.1371/journal.pone.0206679pubmed: 30440016google scholar: lookup
            6. Schnabel CL, Wimer CL, Perkins G, Babasyan S, Freer H, Watts C, Rollins A, Osterrieder N, Wagner B. Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity. BMC Vet Res 2018 Aug 22;14(1):245.
              doi: 10.1186/s12917-018-1563-4pubmed: 30134896google scholar: lookup
            7. Hue ES, Richard EA, Fortier CI, Fortier GD, Paillot R, Raue R, Pronost SL. Equine PBMC Cytokines Profile after In Vitro α- and γ-EHV Infection: Efficacy of a Parapoxvirus Ovis Based-Immunomodulator Treatment. Vaccines (Basel) 2017 Sep 19;5(3).
              doi: 10.3390/vaccines5030028pubmed: 28925977google scholar: lookup
            8. Spiesschaert B, Goldenbogen B, Taferner S, Schade M, Mahmoud M, Klipp E, Osterrieder N, Azab W. Role of gB and pUS3 in Equine Herpesvirus 1 Transfer between Peripheral Blood Mononuclear Cells and Endothelial Cells: a Dynamic In Vitro Model. J Virol 2015 Dec;89(23):11899-908.
              doi: 10.1128/JVI.01809-15pubmed: 26378176google scholar: lookup
            9. Goodman LB, Wimer C, Dubovi EJ, Gold C, Wagner B. Immunological correlates of vaccination and infection for equine herpesvirus 1. Clin Vaccine Immunol 2012 Feb;19(2):235-41.
              doi: 10.1128/CVI.05522-11pubmed: 22205656google scholar: lookup
            10. Soboll Hussey G, Hussey SB, Wagner B, Horohov DW, Van de Walle GR, Osterrieder N, Goehring LS, Rao S, Lunn DP. Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant. Vet Res 2011 Feb 7;42(1):23.
              doi: 10.1186/1297-9716-42-23pubmed: 21314906google scholar: lookup
            11. Ferrari L, De Angelis E, Martelli P, Borghetti P. Swine virus-specific cytotoxic cells producing IFNgamma under different conditions of virus antigenic stimulation. Vet Res Commun 2010 Jun;34 Suppl 1:S63-7.
              doi: 10.1007/s11259-010-9383-4pubmed: 20512626google scholar: lookup
            12. Wagner B, Burton A, Ainsworth D. Interferon-gamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals. Vet Res 2010 Jul-Aug;41(4):47.
              doi: 10.1051/vetres/2010019pubmed: 20374696google scholar: lookup
            13. Paillot R, Robinson C, Steward K, Wright N, Jourdan T, Butcher N, Heather Z, Waller AS. Contribution of each of four Superantigens to Streptococcus equi-induced mitogenicity, gamma interferon synthesis, and immunity. Infect Immun 2010 Apr;78(4):1728-39.
              doi: 10.1128/IAI.01079-09pubmed: 20123710google scholar: lookup
            14. Mealey RH, Littke MH, Leib SR, Davis WC, McGuire TC. Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2. Vet Immunol Immunopathol 2007 Jul 15;118(1-2):121-8.
              doi: 10.1016/j.vetimm.2007.04.001pubmed: 17498813google scholar: lookup
            15. Wagner B, Schnabel CL, Rollins A. Increase in Virus-Specific Mucosal Antibodies in the Upper Respiratory Tract Following Intramuscular Vaccination of Previously Exposed Horses Against Equine Herpesvirus Type-1/4. Vaccines (Basel) 2025 Mar 10;13(3).
              doi: 10.3390/vaccines13030290pubmed: 40266191google scholar: lookup
            16. Holmes CM, Wagner B. Characterization of Nasal Mucosal T Cells in Horses and Their Response to Equine Herpesvirus Type 1. Viruses 2024 Sep 25;16(10).
              doi: 10.3390/v16101514pubmed: 39459849google scholar: lookup
            17. Giessler KS, Goehring LS, Jacob SI, Davis A, Esser MM, Lee Y, Zarski LM, Weber PSD, Hussey GS. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses. J Gen Virol 2024 May;105(5).
              doi: 10.1099/jgv.0.001987pubmed: 38767608google scholar: lookup
            Subscribe to our newsletter
            Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.